# A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct04379167/  
OnCo record `nct04379167` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Linperlisib in Follicular lymphoma, run by Shanghai YingLi Pharmaceutical Co. Ltd., with a status the registry has not verified recently.

## Summary

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT04379167 by Shanghai YingLi Pharmaceutical Co. Ltd., with 140 participants planned, started 2020-12-30 and due to reach its primary completion in 2022-12-30. Interventions recorded: YY-20394. Conditions recorded: Follicular Lymphoma.

Linked to the drug Linperlisib because the registry names it among its interventions and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04379167
- Phase: 2
- Setting: A Phase 2, Single Arm, Open Label Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of YY-20394 in Patients With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma Who Have Failed at Least Two Prior Systemic Therapies.
- Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT04379167: https://clinicaltrials.gov/study/NCT04379167

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Linperlisib](https://onco.cc/drugs/linperlisib/)
- companies: [Shanghai Yingli Pharmaceutical](https://onco.cc/companies/shanghai-yingli/)

---
JSON: https://onco.cc/api/v1/entities/nct04379167.json